论文部分内容阅读
目的探讨血必净注射液联合抗生素治疗急性前列腺炎(AP)的临床疗效。方法选取重庆市万州区第一人民医院外二科2013年3月—2016年3月收治的AP患者98例,随机分为对照组(n=49)和联合组(n=49)。对照组给予左氧氟沙星注射液治疗,联合组在对照组基础上加用血必净注射液治疗,两组患者均持续治疗7d。比较两组患者临床疗效,治疗前后血、尿常规及前列腺液(EPS)WBC、血清C反应蛋白(CRP)及不良反应发生情况和转归〔慢性前列腺炎(CP)〕。结果联合组患者临床治疗总有效率高于对照组(P<0.05)。治疗前,两组患者血WBC、尿WBC、EPS WBC及血清CRP比较,差异无统计学意义(P>0.05);治疗后,联合组患者血WBC、尿WBC、EPS WBC及血清CRP低于对照组(P<0.05)。联合组患者不良发应发生率、CP发生率低于对照组(P<0.05)。结论血必净注射液联合抗生素治疗AP临床疗效确切,可有效缓解机体炎性反应,改善患者预后,且安全性高。
Objective To investigate the clinical efficacy of Xuebijing injection combined with antibiotics in the treatment of acute prostatitis (AP). Methods A total of 98 patients with AP who were admitted to the Second People’s Hospital of Wanzhou District of Chongqing from March 2013 to March 2016 were randomly divided into control group (n = 49) and combination group (n = 49). The control group was treated with levofloxacin injection, the combination group was treated with Xuebijing injection on the basis of the control group, and both groups were treated for 7 days. The clinical curative effect, blood and urine routine and EPS WBC, CRP, adverse reactions and outcomes of chronic prostatitis (CP) were compared between the two groups. Results The total effective rate of clinical treatment in combination group was higher than that in control group (P <0.05). Before treatment, blood WBC, urine WBC, EPS WBC and serum CRP had no significant difference between the two groups (P> 0.05). After treatment, the blood WBC, urinary WBC, EPS WBC and serum CRP in the combined group were lower than those in the control group Group (P <0.05). In the combined group, the incidence of adverse reactions and the incidence of CP were lower than those in the control group (P <0.05). Conclusion Xuebijing injection combined with antibiotics AP clinical curative effect is exact, can effectively alleviate the body inflammatory response, improve patient prognosis, and high safety.